Home Cart Sign in  
Chemical Structure| 448947-81-7 Chemical Structure| 448947-81-7

Structure of Yoda 1
CAS No.: 448947-81-7

Chemical Structure| 448947-81-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Yoda 1 is a Piezo1 channel activator.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Yoda 1

CAS No. :448947-81-7
Formula : C13H8Cl2N4S2
M.W : 355.27
SMILES Code : ClC1=C(CSC2=NN=C(C3=NC=CN=C3)S2)C(Cl)=CC=C1
MDL No. :MFCD00833175
InChI Key :BQNXBSYSQXSXPT-UHFFFAOYSA-N
Pubchem ID :2746822

Safety of Yoda 1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human dermal lymphatic endothelial cells (LECs) 0.5, 1, 2 µM 8 h Yoda1 treatment did not show cytotoxicity. Nat Neurosci. 2024 May;27(5):913-926.
Human dermal lymphatic endothelial cells (LECs) 0.3-2 µM 10 min Yoda1 treatment rapidly induced phosphorylation of CDH5, VEGFR2, VEGFR3, AKT1, and eNOS. Nat Neurosci. 2024 May;27(5):913-926.
mouse pancreatic acinar cells 50 μM To investigate the effect of Yoda1 on intracellular calcium levels, results showed that Yoda1 caused a sustained elevation in intracellular calcium, which was dependent on the presence of extracellular calcium. J Clin Invest. 2020 May 1;130(5):2527-2541.
mouse pancreatic acinar cells 25 μM To investigate the effect of Yoda1 on intracellular calcium levels, results showed that Yoda1 caused an initial transient and sustained elevation in intracellular calcium in the presence of extracellular calcium. J Clin Invest. 2020 May 1;130(5):2527-2541.
cardiomyocytes 30 μM Yoda1-induced Ca2+ responses in cardiomyocytes are mediated by Piezo1, and removal of extracellular Ca2+ abolished the response, indicating Yoda1-induced Ca2+ influx. Nat Commun. 2021 Feb 8;12(1):869.
Primary murine hepatocytes 50 μM 30 min Validate the effect of Yoda-1 on RRAS and HAMP gene expression in primary murine hepatocytes. Results showed that Yoda-1 treatment increased RRAS expression and led to HAMP gene downregulation. Am J Hematol. 2025 Jan;100(1):52-65.
Hep3B cells 15 μM 60 min Activate PIEZO1 and observe its effect on RRAS and HAMP gene expression. Results showed that Yoda-1 treatment increased RRAS expression and led to HAMP gene downregulation. Am J Hematol. 2025 Jan;100(1):52-65.
HEK293T ΔPZ1 cells 30 μM Yoda1 increases the open probability of Piezo1 channels, extending open dwell times and shortening shut dwell times. Proc Natl Acad Sci U S A. 2022 Jul 19;119(29):e2202269119.
HEK293T ΔPZ1 cells 100 μM Yoda1 activates Piezo1 channels, and calcium imaging shows that Yoda1's effect depends on mechanical gating motions. Proc Natl Acad Sci U S A. 2022 Jul 19;119(29):e2202269119.
DU145 cells 50 µM 24 h Yoda1 had a weaker effect on enhancing TRAIL-mediated apoptosis in Bax-deficient DU145 cells. Cell Death Dis. 2019 Nov 4;10(11):837.
MDA-MB-231 cells 10 µM 24 h Yoda1 significantly enhanced TRAIL-mediated apoptosis in MDA-MB-231 cells, significantly reducing cell viability. Cell Death Dis. 2019 Nov 4;10(11):837.
COLO 205 cells 10 µM 24 h Yoda1 significantly enhanced TRAIL-mediated apoptosis in COLO 205 cells, significantly reducing cell viability. Cell Death Dis. 2019 Nov 4;10(11):837.
PC3 cells 10 µM 24 h Yoda1 enhanced TRAIL-mediated apoptosis in PC3 cells, significantly reducing cell viability. Cell Death Dis. 2019 Nov 4;10(11):837.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Down syndrome mouse model Intraperitoneal injection 213 µg/kg Daily for 4 consecutive days Yoda1 treatment significantly reduced CSF accumulation and ventricular enlargement. Nat Neurosci. 2024 May;27(5):913-926.
Mice DMM-induced Osteoarthritis Model Intra-articular injection 150 µg/ml Once a week for 8 weeks To study the effects of Yoda1 on DMM-induced osteoarthritis lesions J Adv Res. 2024 Aug;62:105-117
Mice Pancreatic duct infusion model Pancreatic duct infusion 0.4 mg/kg Single injection, over 10 minutes To investigate the effect of Yoda1 on pancreatitis, results showed that Yoda1 infusion increased all pancreatitis parameters measured (pancreatic edema, serum amylase, pancreatic myeloperoxidase [MPO], and histological scoring), indicating that Yoda1 induced pancreatitis. J Clin Invest. 2020 May 1;130(5):2527-2541.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.81mL

0.56mL

0.28mL

14.07mL

2.81mL

1.41mL

28.15mL

5.63mL

2.81mL

References

 

Historical Records

Categories